Background Air pollution has been proposed as a short-term trigger of multiple sclerosis (MS) relapses, but delayed effects ...

Background To compare relapse and disability outcomes of inebilizumab, azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX) in maintenance-therapy-naive patients with aquaporin-4 ...

Background To investigate whether exposure to pet hamsters may act as a potential trigger for autoimmune cerebellar ataxia (ACA). Methods We conducted a hospital-based case–control study based on our ...

Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with the global epidemiological profile remaining incompletely understood. While previous systematic reviews existed ...

Background The high incidence of in-stent restenosis (ISR) associated with bare-metal stents (BMS) undermines the viability of endovascular treatment as a treatment option for patients with severe ...

Mummery et al 1 outline the recommendations for the appropriate use (AURs) of the amyloid-targeting monoclonal antibody lecanemab in clinical practice in the United Kingdom. These recommendations are ...

Background We aimed to describe neuroimaging features, clinical profiles and long-term outcomes in patients with iatrogenic cerebral amyloid angiopathy (iCAA). Methods We performed a systematic ...

Background Plasma phosphorylated tau (p-tau) 217 test has emerged as a minimally invasive and accessible alternative to positron emission tomography imaging and cerebrospinal fluid analysis for ...

Background Depression is reported as a risk factor, prodromal feature and late consequence of Parkinson’s disease (PD). We aimed to evaluate the timing, neuroanatomy and prognostic implications of ...

Myasthenia gravis (MG) treatment’s landscape has dramatically changed with the approval of novel therapeutics that can provide rapid improvement, including in patients typically considered refractory.

Background The diagnostic value of new criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) for chronic inflammatory demyelinating polyneuropathy (CIDP) is unknown. Methods ...

Correspondence to Dr Gian Marco De Marchis, Neurology and Stroke Center, University Hospital Basel, Basel, BS, Switzerland; gian.demarchis{at}usb.ch Objective The optimal timing to start direct oral ...